These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19802508)

  • 1. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
    Yang L; Sycheva AV; Black DM; Eastell R
    Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
    Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
    Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS; Harsløf T; Langdahl B
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.
    Bai H; Jing D; Guo A; Yin S
    J Int Med Res; 2013 Jun; 41(3):697-704. PubMed ID: 23669294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients.
    Gamsjaeger S; Hofstetter B; Zwettler E; Recker R; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    Osteoporos Int; 2013 Jan; 24(1):339-47. PubMed ID: 23229465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Bubbear JS; Gall A; Middleton FR; Ferguson-Pell M; Swaminathan R; Keen RW
    Osteoporos Int; 2011 Jan; 22(1):271-9. PubMed ID: 20358358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of anthropometric parameters and bone size on bone mineral density using volumetric quantitative computed tomography and dual X-ray absorptiometry at the hip.
    Guglielmi G; van Kuijk C; Li J; Meta MD; Scillitani A; Lang TF
    Acta Radiol; 2006 Jul; 47(6):574-80. PubMed ID: 16875335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.